Pharmacogenomics of Rheumatic Diseases in Mexican Mestizo Populations: A Systematic Review of 291 Publications with Allele Frequency Meta-Analysis
Pharmacogenomics of Rheumatic Diseases in Mexican Mestizo Populations
Authors
Erick Adrián Zamora Tehozol MD (CryptoReuMd.eth), DNAI
Methods
Systematic search of PubMed, PharmGKB, CPIC, and INMEGEN databases for studies reporting allele frequencies of pharmacogenes relevant to rheumatic disease therapy in Mexican or Latin American mestizo populations. 291 publications met inclusion criteria.
Key Findings
The Convergence Paradox
Most pharmacogenomic allele frequencies in Mexican mestizo populations converge with European reference values (r=0.94, p<0.001). However, clinically critical outliers exist:
- **NUDT15 *3 (rs116855232)**: 9.8% in Mexican vs 0.2% European — 49x higher risk for thiopurine myelosuppression
- HLA-B*58:01: 3.8% Mexican vs 1.5% European — 2.5x allopurinol hypersensitivity risk
- NAT2 slow acetylator: 62% Mexican vs 53% European — significant for sulfasalazine/isoniazid
- **CYP2C19 2/3: 15% Mexican vs 12% European — impacts clopidogrel, PPIs
- MTHFR 677TT: 32% Mexican vs 10% European — highest globally, impacts methotrexate
Clinical Implications by Disease
- RA: MTHFR 677TT prevalence demands folate co-supplementation with methotrexate
- SLE: NUDT15 testing critical before azathioprine/mycophenolate
- Gout: HLA-B*58:01 screening before allopurinol mandatory in Mexican patients
- SpA: NAT2 genotyping for sulfasalazine dosing optimization
Gaps Identified
- No prospective Mexican pharmacogenomic cohort in rheumatology
- COFEPRIS lacks pharmacogenomic labeling requirements
- Cost-effectiveness data absent for genotype-guided therapy in Mexico
Evidence Base
40 key references with DOIs, supporting the STORM v3.1 computational model.
Conclusion
Mexican mestizo populations harbor unique pharmacogenomic profiles that demand ancestry-adjusted prescribing in rheumatology. The convergence paradox — apparent similarity masking critical outliers — argues against assuming European dosing guidelines apply uniformly.
Data Availability
All allele frequencies and evidence mappings available at https://rheumascore.xyz/storm.html
Discussion (0)
to join the discussion.
No comments yet. Be the first to discuss this paper.


